These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16309334)

  • 21. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cost-benefit analysis using contingent valuation techniques: a feasibility study in spinal surgery.
    Haefeli M; Elfering A; McIntosh E; Gray A; Sukthankar A; Boos N
    Value Health; 2008; 11(4):575-88. PubMed ID: 18179657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Willingness to pay for public health services in rural Central Java, Indonesia: methodological considerations when using the contingent valuation method.
    Shono A; Kondo M; Ohmae H; Okubo I
    Soc Sci Med; 2014 Jun; 110():31-40. PubMed ID: 24713191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EPIC Studies: Governments Finance, On Average, More Than 50 Percent Of Immunization Expenses, 2010-11.
    Brenzel L; Schütte C; Goguadze K; Valdez W; Le Gargasson JB; Guthrie T
    Health Aff (Millwood); 2016 Feb; 35(2):259-65. PubMed ID: 26858378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage.
    Lim SS; Stein DB; Charrow A; Murray CJ
    Lancet; 2008 Dec; 372(9655):2031-46. PubMed ID: 19070738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of willingness to pay for health services: a systematic review of contingent valuation studies.
    Steigenberger C; Flatscher-Thoeni M; Siebert U; Leiter AM
    Eur J Health Econ; 2022 Dec; 23(9):1455-1482. PubMed ID: 35166973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.
    Glassman A; Cañón O; Silverman R
    Value Health; 2016 Dec; 19(8):913-920. PubMed ID: 27987640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contingent Valuation: A Pilot Study for Eliciting Willingness to Pay for a Reduction in Mortality From Vaccine-Preventable Illnesses for Children and Adults in Bangladesh.
    Odihi D; De Broucker G; Hasan Z; Ahmed S; Constenla D; Uddin J; Patenaude B
    Value Health Reg Issues; 2021 May; 24():67-76. PubMed ID: 33508753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20.
    Ozawa S; Clark S; Portnoy A; Grewal S; Brenzel L; Walker DG
    Health Aff (Millwood); 2016 Feb; 35(2):199-207. PubMed ID: 26858370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reliability and Validity of the Contingent Valuation Method for Estimating Willingness to Pay: A Case of In Vitro Fertilisation.
    Settumba SN; Shanahan M; Botha W; Ramli MZ; Chambers GM
    Appl Health Econ Health Policy; 2019 Feb; 17(1):103-110. PubMed ID: 30315488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An analysis of GAVI, the Global Fund and World Bank support for human resources for health in developing countries.
    Vujicic M; Weber SE; Nikolic IA; Atun R; Kumar R
    Health Policy Plan; 2012 Dec; 27(8):649-57. PubMed ID: 22333685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 78 countries: immunization financing in developing and transitional countries.
    Deroeck D; Levin A
    Health Reform Prior Serv; 1999; ():21-4. PubMed ID: 12222166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Child immunisation is becoming unaffordable in some countries, charity warns.
    Gulland A
    BMJ; 2015 Jan; 350():h303. PubMed ID: 25646956
    [No Abstract]   [Full Text] [Related]  

  • 37. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand.
    Hayman DTS; Marshall JC; French NP; Carpenter TE; Roberts MG; Kiedrzynski T
    Vaccine; 2017 Sep; 35(37):4913-4922. PubMed ID: 28802754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of conditional cash transfers on child health in low- and middle-income countries: a systematic review.
    Owusu-Addo E; Cross R
    Int J Public Health; 2014 Aug; 59(4):609-18. PubMed ID: 24898173
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.